相关实验视频
Updated: Feb 6, 2026

08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
17.0K
不总是自身免疫性肝炎:肝硬化与肝细胞功能障碍患者的自身抗体阳性有关
Ana Isabel Ferreira1,2,3, Mariana Costa Azevedo4, Vitor Macedo Silva1,2,5
1Department of Gastroenterology, Unidade Local de Saúde do Alto Ave, Guimaraes 4835-044, Portugal.
World journal of hepatology
|February 5, 2026
概括
自体免疫性肝炎 (AIH) 在近一半具有阳性自身抗体的患者中未被证实. 在这些情况下,男性性别和更高的受控减弱参数 (CAP) 值预测了非AIH诊断.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 像反核抗体 (ANA) 这样的自身抗体在自身免疫性肝炎 (AIH) 中很常见.
- 然而,在没有自身免疫性疾病的情况下,在代谢功能障碍相关的脂肪性肝病 (MASLD) 中也可能存在 ANA.
- 区分AIH与其他具有阳性自身抗体的肝脏疾病可能是具有挑战性的.
研究的目的:
- 为了确定AIH诊断未得到确认的预测因素.
- 分析与MASLD相关的因素,在患者中具有阳性自身抗体和肝功能障碍.
主要方法:
- 追溯的队列研究81名成年患者肝功能障碍和积极的自身抗体接受肝脏活检.
- 排除已知肝病或活检质量差的患者.
- 分析临床,实验室和组织学数据,包括ANA和受控衰减参数 (CAP).
主要成果:
- 在53.1%的患者中诊断出AIH,在46.9%的患者中诊断出 MASLD.
- 对于AIH,ANA显示高灵敏度 (83.7%),但特异性低 (18.4%).
- 男性性别,糖尿病,肥胖和较高的CAP值与ANA阳性患者的未确认AIH有关.
- 男性性别和更高的CAP值独立预测未经证实的AIH.
结论:
- 几乎一半的肝功能障碍和阳性自身抗体的患者没有接受AIH诊断.
- 男性性别和升高的CAP值是ANA阳性个体中未经证实AIH的独立预测因素.
- 需要进行前性多中心研究来验证这些发现.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System
6.0K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.0K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
247
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
Hepatic Drug Excretion: Influencing Factors
590
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
590
Hepatic Drug Clearance: Role of Transporters
310
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
310
Hepatic Drug Excretion: Enterohepatic Cycling
2.8K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K

